



# SpEDIT

**DOI:**

[10.12688/wellcomeopenres.16405.1](https://doi.org/10.12688/wellcomeopenres.16405.1)

**Document Version**

Final published version

[Link to publication record in Manchester Research Explorer](#)

**Citation for published version (APA):**

Torres-Garcia, S., Di Pompeo, L., Eivers, L., Gaborieau, B., White, S. A., Pidoux, A. L., Kanigowska, P., Yaseen, I., Cai, Y., & Allshire, R. C. (2020). SpEDIT: A fast and efficient CRISPR/Cas9 method for fission yeast. *Wellcome open research*, 5, 274. [274]. <https://doi.org/10.12688/wellcomeopenres.16405.1>

**Published in:**

Wellcome open research

**Citing this paper**

Please note that where the full-text provided on Manchester Research Explorer is the Author Accepted Manuscript or Proof version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version.

**General rights**

Copyright and moral rights for the publications made accessible in the Research Explorer are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

**Takedown policy**





If you believe that this document breaches copyright please refer to the University of Manchester's Takedown Procedures [<http://man.ac.uk/04Y6Bo>] or contact [uml.scholarlycommunications@manchester.ac.uk](mailto:uml.scholarlycommunications@manchester.ac.uk) providing relevant details, so we can investigate your claim.





METHOD ARTICLE

# *SpEDIT*: A fast and efficient CRISPR/Cas9 method for fission yeast [version 1; peer review: 3 approved]

Sito Torres-Garcia <sup>1</sup>, Lorenza Di Pompeo<sup>1</sup>, Luke Eivers<sup>1</sup>, Baptiste Gaborieau <sup>1</sup>, Sharon A. White<sup>1</sup>, Alison L. Pidoux<sup>1</sup>, Paulina Kanigowska<sup>2</sup>, Imtiyaz Yaseen <sup>1</sup>, Yizhi Cai<sup>2,3</sup>, Robin C. Allshire <sup>1</sup>

<sup>1</sup>Wellcome Centre for Cell Biology and Institute of Cell Biology, School of Biological Sciences, University of Edinburgh, Mayfield Road, Edinburgh, EH9 3BF, UK

<sup>2</sup>School of Biological Sciences, University of Edinburgh, Mayfield Road, Edinburgh, EH9 3BF, UK

<sup>3</sup>Present address: Manchester Institute of Biotechnology, University of Manchester, Manchester, M1 7DN, UK

**V1** First published: 24 Nov 2020, 5:274  
<https://doi.org/10.12688/wellcomeopenres.16405.1>  
 Latest published: 24 Nov 2020, 5:274  
<https://doi.org/10.12688/wellcomeopenres.16405.1>

## Abstract





The CRISPR/Cas9 system allows scarless, marker-free genome editing. Current CRISPR/Cas9 systems for the fission yeast *Schizosaccharomyces pombe* rely on tedious and time-consuming cloning procedures to introduce a specific sgRNA target sequence into a Cas9-expressing plasmid. In addition, Cas9 endonuclease has been reported to be toxic to fission yeast when constitutively overexpressed from the strong *adh1* promoter. To overcome these problems we have developed an improved system, *SpEDIT*, that uses a synthesised Cas9 sequence codon-optimised for *S. pombe* expressed from the medium strength *adh15* promoter. The *SpEDIT* system exhibits a flexible modular design where the sgRNA is fused to the 3' end of the self-cleaving hepatitis delta virus (HDV) ribozyme, allowing expression of the sgRNA cassette to be driven by RNA polymerase III from a tRNA gene sequence. Lastly, the inclusion of sites for the *BsaI* type IIS restriction enzyme flanking a GFP placeholder enables one-step Golden Gate mediated replacement of GFP with synthesized sgRNAs for expression. The *SpEDIT* system allowed a 100% mutagenesis efficiency to be achieved when generating targeted point mutants in the *ade6<sup>+</sup>* or *ura4<sup>+</sup>* genes by transformation of cells from asynchronous cultures. *SpEDIT* also permitted insertion, tagging and deletion events to be obtained with minimal effort. Simultaneous editing of two independent non-homologous loci was also readily achieved. Importantly the *SpEDIT* system displayed reduced toxicity compared to currently available *S. pombe* editing systems. Thus, *SpEDIT* provides an effective and user-friendly CRISPR/Cas9 procedure that significantly improves the genome editing toolbox for fission yeast.

## Open Peer Review

Reviewer Status 

Invited Reviewers

	1	2	3
<b>version 1</b>			
24 Nov 2020	report	report	report

1. **Antony Carr** , University of Sussex, Brighton, UK
2. **Sophie Martin** , Universite de Lausanne, Lausanne, Switzerland
3. **Sigurd Braun** , Ludwig Maximilians University of Munich, Martinsried, Germany  
**Thomas van Emden** , Ludwig Maxilians University of Munich, Martinsried, Germany

Any reports and responses or comments on the article can be found at the end of the article.

## Keywords

CRISPR/Cas9, gene editing, gene tagging, *S. pombe*, fission yeast

**Corresponding author:** Robin C. Allshire ([Robin.Allshire@ed.ac.uk](mailto:Robin.Allshire@ed.ac.uk))

**Author roles:** **Torres-Garcia S:** Conceptualization, Investigation, Methodology, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing; **Di Pompeo L:** Investigation; **Eivers L:** Investigation; **Gaborieau B:** Investigation; **White SA:** Investigation, Methodology; **Pidoux AL:** Methodology, Writing – Review & Editing; **Kanigowska P:** Methodology; **Yaseen I:** Investigation; **Cai Y:** Resources; **Allshire RC:** Conceptualization, Funding Acquisition, Methodology, Resources, Supervision, Writing – Review & Editing

**Competing interests:** No competing interests were disclosed.

**Grant information:** S. T-G. is supported by the Darwin Trust of Edinburgh. S. T-G., L. D. P., L. E., and B. G. were supported by Erasmus+ traineeships. I. Y. is supported by an EMBO Long Term Fellowship (EMBO ALTF 130-2018). R. C. A. is a Wellcome Principal Research Fellow (095021, 200885); the Wellcome Centre for Cell Biology is supported by core funding from Wellcome (203149).

*The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

**Copyright:** © 2020 Torres-Garcia S *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**How to cite this article:** Torres-Garcia S, Di Pompeo L, Eivers L *et al.* *SpEDIT: A fast and efficient CRISPR/Cas9 method for fission yeast* [version 1; peer review: 3 approved] Wellcome Open Research 2020, 5:274 <https://doi.org/10.12688/wellcomeopenres.16405.1>

**First published:** 24 Nov 2020, 5:274 <https://doi.org/10.12688/wellcomeopenres.16405.1>

## Introduction

The fission yeast *Schizosaccharomyces pombe* is a powerful model organism widely used in cellular and molecular biology (Fantes & Hoffman, 2016). Traditionally, gene manipulation in *S. pombe* is achieved by transforming a DNA construct that includes the desired change alongside a selectable marker. The DNA construct integrates in the genome via flanking regions that target the genomic locus of interest. DNA constructs vary depending on the application but commonly consist of a sole PCR product that comprises an insertion, deletion or tagging cassette amplified from an existing plasmid (Bähler *et al.*, 1998). Albeit convenient, this approach results in a selectable marker integrated at the target locus, consequently disrupting the local genomic context and limiting the availability of markers for subsequent manipulations.

The prokaryotic CRISPR/Cas9 system enables flexible and scarless genome editing without the necessity of selectable markers escorting the introduced DNA change and disturbing the local genomic environment (Hsu *et al.*, 2014; Jinek *et al.*, 2012). Adapted from a genome defence mechanism against invading DNA, the engineered minimal CRISPR/Cas9 system consists of a Cas9 endonuclease and a single-guide RNA (sgRNA) chimera that contains both the trans-activating CRISPR RNA and the targeting CRISPR RNA (Jinek *et al.*, 2012). The sgRNA sequence targets the system to a defined genomic location where the Cas9 endonuclease binds to a protospacer adjacent motif (PAM). The Cas9 enzyme then creates a double-strand break (DSB) three base pairs upstream of the PAM site in the protospacer sequence (Jinek *et al.*, 2012). Following DSB generation, repair is executed either through error-prone non-homologous end-joining (NHEJ), where strand end resection and subsequent repair frequently induce indels, or through high-fidelity homology-directed repair (HDR). HDR involves recombination via sequence homology and therefore can be exploited to generate precise mutations by providing a DNA editing template that contains the required DNA change and engages in homologous recombination (HR) with the cleaved region (Hsu *et al.*, 2014).

Implementation of the CRISPR/Cas9 system in *S. pombe* has been previously described in several reports (Fernandez & Berro, 2016; Hayashi & Tanaka, 2019; Jacobs *et al.*, 2014; Rodríguez-López *et al.*, 2016; Zhao & Boeke, 2018; Zhang *et al.*, 2018). A useful web-tool, CRISPR4P, was also developed to support the design of sgRNAs and oligonucleotides required to perform CRISPR/Cas9-mediated gene deletions (Rodríguez-López *et al.*, 2016).

To date, all CRISPR/Cas9 systems for *S. pombe* utilise the promoter/leader sequence of K RNA (*rrk1*) and a hammerhead ribozyme (HHR) for sgRNA cassette expression (Jacobs *et al.*, 2014). A humanised Cas9 endonuclease expressed from the strong *adh1* promoter was used in the original *S. pombe* system (Jacobs *et al.*, 2014). The resulting high levels of the Cas9 endonuclease were found to be detrimental for *S. pombe* growth. This Cas9 toxicity was partially bypassed

by co-expression of the sgRNA and the Cas9 enzyme from a single plasmid (Jacobs *et al.*, 2014).

Cloning of a sgRNA target into the single sgRNA/Cas9 plasmid was originally executed via *CspCI* digestion (Jacobs *et al.*, 2014). This procedure proved to be extremely inefficient due to the large plasmid size and the inconsistency in available commercial *CspCI* preparations (Rodríguez-López *et al.*, 2016). A subsequent study attempted to overcome this problem by implementing a PCR-based method in which a sgRNA target is introduced into a single sgRNA/Cas9 plasmid by using overlapping PCR primers that contain the sgRNA sequence (pMZ379 plasmid, Rodríguez-López *et al.*, 2016). Although an improvement over the initial system, this PCR-based method generated only a low frequency of bacterial colonies that contain correct and intact constructs. As a consequence, the required screening makes the entire process inefficient and time consuming.


To circumvent issues pertaining to Cas9 toxicity and inefficient sgRNA cloning procedures, here we report the development of *SpEDIT*, an improved CRISPR/Cas9 system for the efficient manipulation of the fission yeast genome. *SpEDIT* employs a highly effective one-step Golden Gate cloning strategy for the insertion of sgRNAs, that in combination with the use of a GFP placeholder allows visual screening for identification of positive clones. The Cas9 endonuclease gene implemented in this system is codon-optimised for expression in *S. pombe* and driven by the medium strength promoter *adh15*, resulting in reduced toxicity associated with Cas9 levels. *SpEDIT* can generate targeted *ade6* and *ura4* point mutants in asynchronous cells with 100% mutagenesis efficiency. Moreover, *SpEDIT* allows simultaneous editing at two non-homologous genes at distinct locations in the *S. pombe* genome, as well as seamless insertion, deletion and tagging at *S. pombe* loci. *SpEDIT* provides an efficient and simple CRISPR/Cas9 method to easily manipulate the genome of the fission yeast.

## Results

### The *SpEDIT* system

The *SpEDIT* system has been developed to address the two main complications associated with existing CRISPR/Cas9 methods for *S. pombe*: toxicity associated with Cas9 overexpression, and laborious cloning procedures required to insert a specific sgRNA target sequence into a Cas9-containing plasmid. An overview of the *SpEDIT* system is provided (Figure 1) along with a full protocol (see Methods).

High levels of human codon-optimised Cas9 endonuclease constitutively expressed from the exceptionally strong *adh1* promoter (400 RNA molecules/cell, PomBase, Lock *et al.*, 2019) lead to reduced cell growth in *S. pombe* (Jacobs *et al.*, 2014). A recent report attempted to solve this toxicity problem by expressing the human codon-optimised Cas9 under control of the repressible *nmt41* promoter (Hayashi & Tanaka, 2019). Although this approach does generate



**Figure 1. SpEDIT provides a fast and effective CRISPR/Cas9 method to manipulate the genome of *Schizosaccharomyces pombe*.** Diagram illustrating the required steps for *S. pombe* strain construction using SpEDIT. For a full protocol see methods. sgRNA, single guide RNA. HR template, homologous recombination donor template.


mutations, it requires the non-ideal use of minimal media and relies on auxotrophic (*ura4* or *leu1*) strains to allow plasmid selection. Moreover, the mutagenesis efficiency obtained was dependent on the selectable marker employed.

To overcome the toxicity related to high levels of humanised Cas9, we synthesized a Cas9 gene codon-optimised for expression in *S. pombe* (SpCas9) that is transcribed from

the medium strength *adh15* promoter (Yamagishi *et al.*, 2008). This *adh15*-SpCas9 gene is carried on a new plasmid, pLSB, that contains a choice of dominant selectable markers. Versions bearing *natMX6*, *kanMX6* or *hphMX6* markers are available, thereby allowing the SpEDIT system to be employed on fission yeast strains that harbour various manipulations where other selectable markers are already present (Figure 2A).

Eukaryotic CRISPR/Cas9 systems usually rely on snRNA or snoRNA RNA polymerase III (RNAPIII) promoters for transcription of the sgRNA cassette (Cong *et al.*, 2013). However, characterised *S. pombe* RNAPIII genes contain promoter elements within the transcribed region, preventing their use for generating accurately positioned 5' ends, and RNA polymerase II (RNAPII) promoters generally do not generate transcripts with precise 5' and 3' ends. Consequently, all sgRNA expression systems for *S. pombe* so far utilise the *rrk1* promoter plus its downstream 5' untranslated region which generates a RNAPII transcript with a cleavable leader RNA (Jacobs *et al.*, 2014). Insertion of sgRNA sequences targeting genomic regions of interest into the *rrk1* sgRNA expression cassette in current CRISPR/Cas9 systems for *S. pombe* relies on slow and arduous cloning procedures involving either traditional restriction digestion (Hayashi & Tanaka, 2019; Jacobs *et al.*, 2014) or PCR over a long template (Rodríguez-López *et al.*, 2016). An alternative method that uses *in vivo* gap repair to assemble a gapped Cas9-encoding plasmid and a PCR-amplified sgRNA fragment into a single circular plasmid has been reported (Zhang *et al.*, 2018). Although this method provided an advance, this system still utilises humanised Cas9 expressed from the very strong *adh1* promoter, which consequently reduces cell growth due to Cas9-associated toxicity.

It has previously been shown that the upstream tRNA<sup>Ser</sup> gene of an *S. pombe* tRNA<sup>Ser</sup>-tRNA<sup>Met</sup> gene pair drives RNAPIII expression of the downstream tRNA<sup>Met</sup> gene (Hottinger-Werlen *et al.*, 1985). We therefore use this tDNA<sup>Ser</sup> to drive sgRNA expression in *S. pombe*. The resulting SpEDIT system employs a modular design where sgRNAs are expressed from this tDNA<sup>Ser</sup> sequence and fused to the hepatitis delta virus ribozyme (HDV), as previously described for *Saccharomyces cerevisiae* (Ryan *et al.*, 2014). The tDNA<sup>Ser</sup> acts as a RNAPIII promoter and the self-cleaving ribozyme protects and defines the 5' end of the resulting sgRNA (Figure 2A and B). The presence of the HDV ribozyme was shown to result in a six-fold increase in sgRNA abundance and this correlated with high targeting efficiency in *S. cerevisiae* (Ryan *et al.*, 2014). To facilitate cloning of sgRNA target sequences into this tDNA/HDV expression cassette, we placed sites for the *BsaI* type IIS restriction enzyme on each side of a GFP placeholder, thereby allowing one-step insertion of sgRNAs via Golden Gate cloning. Importantly, this strategy also permits visual screening to identify colonies that have lost the green GFP fluorescence signal indicating that the GFP has been successfully replaced with an incoming sgRNA (Figure 2B and C).



**Figure 2. The *SpEDIT* pLSB plasmid allows one-step insertion of sgRNAs via Golden Gate cloning.** **A.** Map of pLSB plasmid. Full sequence is available scanning the QR code in [Figure 1](#) or at [allshirelab.com/spedit](http://allshirelab.com/spedit). Versions with *natMX6* (cloNAT), *kanMX6* (G418) or *hphMX6* (hygromycin) *S. pombe* resistance markers are available. A Cas9 codon optimised for *S. pombe* (SpCas9) is expressed from the *adh15* promoter (*Padh15*). **B.** Diagram of sgRNA cassette and cloning procedure. sgRNA cassette expression is driven by a tRNA<sup>Ser</sup> Pol III promoter (purple block arrow). A self-cleaving hepatitis delta virus (HDV) ribozyme is located at the 5' end of the sgRNA cassette (red block arrow). A superfolder green fluorescent protein (sfGFP) is used as placeholder (green block arrow). *BsaI* sites flanking sfGFP allow one-step insertion of a sgRNA target (light blue block arrow) into the sgRNA scaffold (grey block arrow) via Golden Gate cloning. The Pol III terminator sequence from *S. cerevisiae SUP4* (tRNA<sup>Pro</sup>) is present at the 3' end of the sgRNA cassette (black block). **C.** The sfGFP placeholder allows cultures carrying empty (green) pLSB plasmids to be distinguished from sgRNA-loaded (non-green) pLSB plasmids. sgRNA, single guide RNA.

*SpEDIT* can generate targeted *ade6* and *ura4* point mutants in asynchronous cells with 100% mutagenesis efficiency


To assess the performance of the *SpEDIT* system in comparison to the existing pMZ379 system ([Rodríguez-López et al., 2016](#)), we targeted the *ade6*<sup>+</sup> and *ura4*<sup>+</sup> genes and provided HR templates that disable the PAM (NGG) sequence downstream of the sgRNA target to generate premature STOP codon mutations ([Figure 3A](#)). *ade6*<sup>+</sup> and *ura4*<sup>+</sup> mutations can be easily scored due to their characteristic phenotypes: *ade6* mutants, pink colonies develop on low (1/10) adenine-containing plates; *ura4* mutants, cannot grow in the absence of supplementing uracil (uracil auxotrophy) but can grow in the presence of counterselective 5-fluoroorotic acid (FOA resistant) ([Figure 3B](#)).

We scored cloNAT-resistant colonies after electroporation of asynchronous cultures with either *SpEDIT*/pLSB or pMZ379


plasmids expressing sgRNA designed to mediate cleavage within the *ade6*<sup>+</sup> or *ura4*<sup>+</sup> genes in the presence or absence of an HR template homologous to *ade6*<sup>+</sup> or *ura4*<sup>+</sup>, respectively. The results revealed that both pLSB and pMZ379 plasmids can generate targeted mutations in *ade6*<sup>+</sup> and *ura4*<sup>+</sup> with 100% efficiency when a matching HR template was co-transformed ([Figure 3C](#)). However, when an HR template targeting a different gene or no HR template was provided, the number of cloNAT-resistant colonies obtained was dramatically reduced. This decrease in transformant number in the absence of an HR template is consistent with futile cleavage-repair cycles where the persistence of a double strand break prevents cell division and thus colony formation ([Figure 3C](#)).

Sequence analysis of the resulting *ade6* and *ura4* mutants showed that when a matching HR template was co-transformed, all clones analysed harboured the mutation provided by the


**A** sgRNA-loaded pLSB or pMZ379 (sgRNA + Cas9)




**B**



**C** Asynchronous cells



**D** G1-synchronized cells



**E** Asynchronous cells

sgRNA	HR template	% Analysed colonies (n=5)		
		Edited	Other mutation at PAM	No mutation
pLSB	ade6	100%		
	ade6	ura4		100%
	-	-		*
	ura4	ade6		100%
	ura4	ura4	100%	
	-	-		100%
pMZ379	ade6	100%		100%
	ade6	ura4		100%
	-	-		100%
	ura4	ade6		100%
	ura4	ura4	100%	
	-	-		*

G1-synchronized cells

sgRNA	HR template	% Analysed colonies (n=5)		
		Edited	Other mutation at PAM	No mutation
pLSB	ade6	100%		
	ade6	ura4		100%
	-	-		100%
	ura4	ade6		100%
	ura4	ura4	80%	20%
	-	-		100%
pMZ379	ade6	80%	20%	100%
	ade6	ura4		100%
	-	-		100%
	ura4	ade6		100%
	ura4	ura4	40%	60%
	-	-		100%

**Figure 3. *SpEDIT* can generate targeted *ade6* and *ura4* point mutants in asynchronous cells with 100% mutagenesis efficiency.**

**A.** Schematic of experiment to generate targeted *ade6* and *ura4* point mutants. A sgRNA-loaded pLSB or pMZ379 plasmid was co-transformed with an HR template that creates a premature STOP codon by disabling the PAM (NGG) sequence. sgRNA and HR template sequences for *ade6* and *ura4* are shown. Full HR template sequences can be found in [Table 1](#). **B.** After transformation, cloNAT-resistant colonies were picked and re-streaked to non-selective YES plates. Cells were then replica-plated to indicated media to assess their phenotype. Representative plates from two independent experiments are shown. Quantification is shown in **C–D**. **C–D.** Percentage of cloNAT-resistant transformants displaying a mutant phenotype (pink cells, *ade6*; uracil auxotrophy and FOA resistance, *ura4*) after asynchronous (**C**) or G1-synchronized (**D**) wild-type cells were transformed with a sgRNA-loaded *SpEDIT*/pLSB (developed here, [Figure 2](#)) or pMZ379 ([Rodríguez-López et al., 2016](#)) plasmid targeting *ade6*<sup>+</sup> or *ura4*<sup>+</sup> (or no sgRNA plasmid as control). An HR template targeting the same or a different gene was co-transformed as indicated. n = number of cloNAT-resistant colonies assayed. Note that when an HR template targeting a different gene or no HR template was co-transformed into asynchronous cells, the number of cloNAT-resistant colonies obtained was drastically reduced. Experiment was repeated twice with similar results. **E.** For each condition in **C–D**, five colonies displaying the mutant phenotype (or 5 cloNAT-resistant colonies for no sgRNA plasmids) were taken and the gene targeted by the sgRNA was sequenced to confirm changes in its DNA sequence. Both *ade6* and *ura4* were sequenced when no sgRNA was used. Edited clones harbour the change contained in the corresponding HR template. Other mutations at PAM disrupt the PAM (NGG) sequence and the corresponding gene coding sequence. For asynchronous cells transformed with pLSB-*ura4* (no HR template) and pMZ379-*ade6* (no HR template) only two and one colonies were respectively obtained and analysed. \* No colonies were obtained for these conditions. sgRNA, single guide RNA. PAM, proto-spacer adjacent motif. HR, homologous recombination donor template. N/S, non-selective medium. FOA, 5-fluoroorotic acid.

HR template ([Figure 3E](#), left). However, a variety of mutations that disable the PAM sequence and ultimately disrupt the coding sequence of each gene were detected in mutants generated when a non-homologous HR template (targeting a different gene to the sgRNA) or no HR template was provided ([Figure 3E](#), left).

A previous study suggested that G1 synchronization of *S. pombe* cultures by nitrogen starvation prior to CRISPR/Cas9-mediated genome editing enhances transformation and deletion efficiencies ([Rodríguez-López et al., 2016](#)). The rationale for this was that in G1 only one copy of a target locus would need to be modified as opposed to the two copies that are present in G2 cells. The remodelled transcriptional programme of G1 cells was also expected to render genomic regions more open ([Mata et al., 2002](#)), and thus increase accessibility to the editing machinery.

We therefore compared the performance of the *SpEDIT* system (pLSB plasmid) versus the existing pMZ379 system (pMZ379 plasmid) at generating *ade6* and *ura4* mutations using G1-synchronized *S. pombe* cells as previously described ([Rodríguez-López et al., 2016](#)). This comparison revealed that the pLSB plasmid is more efficient than the pMZ379 plasmid at generating mutations in G1-synchronized cells ([Figure 3D](#)). However, even when a matching HR template was co-transformed, the mutagenesis efficiencies obtained with G1 cells were lower than that of asynchronous cells (pLSB→*ade6*, 92% G1 versus 100% Asynchronous; pLSB→*ura4*, 85% G1 versus 100% Asynchronous) ([Figure 3D](#)).

Moreover, sequence analysis revealed that even when a matching HR template was co-transformed into G1 cells, not all mutant clones harboured the anticipated mutation that was presented by the HR template ([Figure 3E](#), right). This lack of accuracy is likely due to the suppression of the HR pathway that is known to occur in G1 cells ([Orthwein et al., 2015](#); [Trickey et al., 2008](#)).


Taken together, our results show that the *SpEDIT* system can generate targeted mutations at *ade6*<sup>+</sup> and *ura4*<sup>+</sup> with 100% mutagenesis efficiency using asynchronous cell cultures. Notably, our experiments show that G1 synchronization of *S. pombe* cells prior transformation has a detrimental effect on mutagenesis efficiency regardless of the CRISPR/Cas9 system used.

***SpEDIT* shows reduced toxicity compared with the current pMZ379 CRISPR/Cas9 system in asynchronous cells**

To determine if the *SpEDIT* system leads to reduced toxicity compared to the current pMZ379 system, we measured colony area on selection plates after transforming asynchronous or G1-synchronized cultures with pLSB or pMZ379 plasmids targeting *ade6*<sup>+</sup> or *ura4*<sup>+</sup> (or empty plasmid controls) in the presence of a matching HR template. The colony area (equivalent to colony size) was found to be greater when asynchronous cells were transformed with pLSB as opposed to pMZ379 ([Figure 4A](#)). The resulting difference in colony size was independent of the presence of a sgRNA, indicating that excessive levels of Cas9 alone, and not Cas9 targeting to a genomic locus, are sufficient to cause the observed toxicity ([Figure 4A](#)). Consistent with this, the toxicity of *adh1*-Cas9 has also been shown to be independent of Cas9 catalytic activity ([Ciccaglione, 2015](#)).

In contrast, colony area measurements of pLSB and pMZ379 transformants obtained from G1-synchronized cells revealed no major difference in resulting colony size ([Figure 4B](#)). This indicates that the toxicity related to high levels of catalytically active Cas9 is more prominent when transforming asynchronous cells. The lack of apparent toxicity in G1 cells is likely due to the known upregulation of non-homologous end joining-mediated repair and the suppression of homologous recombination repair that is known to occur at this cell cycle stage ([Orthwein et al., 2015](#)).





**Figure 4. *SpEDIT* shows reduced toxicity compared with the current pMZ379 *S. pombe* CRISPR/Cas9 system in asynchronous cells. A–B.** Colony area measurements of asynchronous (A) or G1-synchronized (B) wild-type cells transformed with pLSB or pMZ379 plasmids and indicated HR templates growing on selective cloNAT-containing plates (same experiment as Figure 3). Colony area was quantified (cm<sup>2</sup>) using ImageJ. sgRNA, single guide RNA. HR, homologous recombination donor template.

### *SpEDIT* allows simultaneous editing at two non-homologous genes at distinct locations in the *S. pombe* genome

The availability of pLSB versions bearing different dominant selectable markers presented the opportunity to test if the simultaneous editing of two different non-homologous loci by co-transformation with and selection of two distinct pLSB plasmids expressing different sgRNAs was possible.


To evaluate the possibility of simultaneous editing, we targeted two non-homologous genes, *clr5*<sup>+</sup> and *meu27*<sup>+</sup>, located on different chromosomes (I and III, respectively) in wild-type cells using pLSB-cloNAT and pLSB-hygromycin plasmids that express sgRNAs designed to target *clr5*<sup>+</sup> and *meu27*<sup>+</sup>, respectively (Figure 5A). We co-transformed two HR templates that generate point mutations in *clr5*<sup>+</sup> (*clr5-Q264STOP*) and *meu27*<sup>+</sup> (*meu27-S100Y*), and concomitantly disabled both corresponding PAM sequences (Figure 5A and B). These mutations (*clr5-Q264STOP* and *meu27-S100Y*) had previously been identified in a proportion of heterochromatin-dependent epimutants resistant to caffeine (Torres-Garcia *et al.*, 2020).

Sequencing of *clr5* and *meu27* in ten resulting cloNAT and hygromycin doubly resistant co-transformants revealed that two harboured both of the expected DNA changes. Five clones carried mutations in only one of the two targeted genes or bore mutations that uniquely affected the PAM sequence, and three clones displayed neither of the anticipated changes (Figure 5C). Importantly, whole-genome sequencing of one of the isolates that contained both expected gene editing events revealed no additional genetic changes (SNPs or indels) in coding regions of the genome (Torres-Garcia *et al.*, 2020).

These results demonstrate that our improved system can be utilised to perform simultaneous gene editing at two distant, non-homologous *S. pombe* loci, albeit with reduced efficiency relative to the frequency of editing of a single locus.

### Seamless insertion, deletion and tagging at *S. pombe* loci using *SpEDIT*

To assess the capabilities of *SpEDIT* in additional gene editing tasks, we utilised it to perform insertion, deletion and tagging at single *S. pombe* loci. Specifically, using *SpEDIT*, we inserted *tetO* binding sites downstream of the *cup1*<sup>+</sup> (SPBC17G9.13c) gene (Figure 6A). *tetO* binding sites allow tethering of proteins such as TetR-Clr4\* and heterochromatin formation in the vicinity of the tethering site (Audergon *et al.*, 2015; Ragunathan *et al.*, 2015). A fusion-PCR construct containing 4*tetO* sites with 120 bp homology arms flanking the desired insertion site was used as the HR template (see Table 1 for sgRNA and HR template sequences). Correct insertion of the *cup1:4tetO* HR template resulted in ablation of the PAM sequence. Furthermore, we used *SpEDIT* to seamlessly fuse GFP in frame with the 3' end of the of *cup1*<sup>+</sup> gene to produce Cup1-GFP (Figure 6B). To generate the *cup1-gfp* HR template, the *GFP* open reading frame was amplified with oligonucleotides that had long extensions homologous to sequence immediately up-stream and downstream of the normal *cup1*<sup>+</sup> STOP codon. This HR template also carried a DNA change (in the 5' long oligo) designed to disable the PAM sequence without altering the Cup1 protein sequence. Resulting strains were confirmed to carry the planned *cup1:4tetO* or Cup1-GFP insertions in the absence of any associated selectable marker and have been utilised to show that heterochromatin-mediated silencing of *cup1*<sup>+</sup> is sufficient to drive caffeine resistance in wild-type cells and that Cup1-GFP localises to mitochondria (Torres-Garcia *et al.*, 2020).




**Figure 5. SpEDIT allows simultaneous editing at two non-homologous genes at distinct locations in the *S. pombe* genome.**

**A.** Schematic of experiment to simultaneously generate targeted point mutations in *clr5*<sup>+</sup> and *meu27*<sup>+</sup>. Two sgRNA-loaded pLSB plasmids (with different selection markers) were co-transformed with two HR templates that create the desired point mutations and disable the corresponding PAM (NGG) sequence. Transformed cells were then selected on selective plates containing both cloNAT and hygromycin. **B.** sgRNA and HR template sequences for *clr5* (left) and *meu27* (right) are shown, along with Sanger sequencing chromatograms for a successfully edited clone. Full HR template sequences can be found in Table 1. **C.** Percentage of cloNAT- and hygromycin-resistant transformants harbouring the targeted mutations in *clr5* and *meu27* as revealed by Sanger sequencing. sgRNA, single guide RNA. HR, homologous recombination donor template.

Epe1 is a putative histone demethylase that acts to prevent heterochromatin island formation (Sorida *et al.*, 2019; Wang *et al.*, 2015; Zofall *et al.*, 2012). Using SpEDIT, we deleted the *epe1*<sup>+</sup> coding sequence (Figure 6C). The *epe1Δ* HR template employed contained 80 bp arms homologous to sequences immediately flanking the *epe1*<sup>+</sup> coding sequence as previously used for the deletion of other sequences (Rodríguez-López *et al.*, 2016). Correct deletion of the *epe1*<sup>+</sup> coding sequence results in loss of the sgRNA target and PAM sequences. In addition, we seamlessly inserted a sequence to encode a 3xFLAG epitope tag between the *epe1*<sup>+</sup> gene promoter and the 5' end of the *epe1*<sup>+</sup> coding sequence to allow the production of N-terminally 3xFLAG-tagged Epe1 without any associated selectable marker (Figure 6D). To accomplish this, an in-frame *epe1-3xflag-epe1* HR template

containing 50 bp arms homologous to the sequence immediately flanking the *epe1*<sup>+</sup> start codon was used. Correct insertion of the *epe1-3xflag-epe1* sequence resulted in loss of both the sgRNA target and the PAM sequence. The resulting *epe1Δ* and 3xFLAG-Epe1 strains were recently utilised to study the role of Epe1 in ectopic heterochromatin island formation following caffeine exposure (Torres-Garcia *et al.*, 2020). Notably, whole-genome sequencing of the *cup1:4xtetO* and *epe1Δ* strains revealed no additional genetic changes (SNPs or indels) in coding regions of the genome (Torres-Garcia *et al.*, 2020).

In the four distinct genome editing scenarios described above, a maximum of eight primary transformants needed to be screened to obtain at least one that exhibited the desired



**Figure 6. SpEDIT allows seamless insertion, deletion and tagging at *S. pombe* loci.** For sgRNA and HR template sequences see Table 1. **A.** *4xtetO* binding sites were inserted downstream of *cup1*<sup>+</sup>. Sanger sequencing chromatograms covering the insert junctions are shown for a successfully edited clone. PCR primers (half arrows) flanking the insert were used to amplify products from wild-type (wt) and edited strains. **B.** Cup1 was C-terminally tagged with a green fluorescent protein (GFP). Sanger sequencing chromatogram covering the gene-tag junction is shown for a successfully edited clone. Western blot using anti-GFP antibody was performed on wild-type (wt) and edited strains. **C.** The coding sequence of *epe1*<sup>+</sup> was deleted. Sanger sequencing chromatogram covering the deletion junction is shown for a successfully edited clone. PCR primers (half arrows) flanking the deletion (and within the *epe1*<sup>+</sup> coding sequence as control) were used to amplify products from wild-type (wt) and edited strains. **D.** Epe1 was N-terminally tagged with three FLAG epitopes. Sanger sequencing chromatogram covering the gene-tag junction is shown for a successfully edited clone. Western blot using anti-FLAG antibody was performed on wild-type (wt) and edited strains.

sequence change. We therefore conclude that *SpEDIT* markedly speeds up the process of generating accurate insertion, deletion and tagging events at a variety of *S. pombe* loci.

## Discussion

Here we report the development of *SpEDIT*, an optimized CRISPR/Cas9 editing system and method for the fission yeast, *S. pombe* (Figure 1 and Figure 2). *SpEDIT* makes use of Cas9 codon-optimised for expression in *S. pombe* that, coupled with the incorporation of a tDNA<sup>Ser</sup>/HDV ribozyme

sgRNA expression cassette (Ryan *et al.*, 2014), achieves 100% efficiency in generating mutations at targeted *ade6*<sup>+</sup> or *ura4*<sup>+</sup> genes in asynchronous cells (Figure 3). A high mutagenesis efficiency was also obtained with the pre-existing pMZ379 system in asynchronous cells (Jacobs *et al.*, 2014; Rodríguez-López *et al.*, 2016). However, *SpEDIT* displayed reduced toxicity by removing the detrimental physiological effects associated with high humanised Cas9 endonuclease expression and consequently speeds up the genome editing process (Figure 4). In addition, our analysis indicates that the

**Table 1. sgRNA and HR templates used in this study.** All sgRNA sequences used were obtained using CRISPR4P (Rodríguez-López *et al.*, 2016).

Name	Sequence
<i>ade6</i> - sgRNA	TTGATAGCAACAGTGGCGAC
<i>ura4</i> - sgRNA	CCTTGATAATACCCTCGCC
<i>meu27</i> - sgRNA	TATTAGCCTTTGAAGATTT
<i>clr5</i> - sgRNA	AGCTTGTGGCTGACCGTTAA
<i>cup1:4xtetO</i> - sgRNA	ATTTCTTTTGTCTTACGGTC
<i>cup1</i> -GFP - sgRNA	GCTCAGGCTAAACGTCGGAA
<i>epe1</i> - sgRNA	GGACTTTTAAGATGGATTCC
<i>ade6</i> - HR template	GCAATGACACCTCTTCCAGTAATCGGCGTTCTGTAAAAGGAAGCACTCTTGACGGAGTTGACTCTCTTTAGTCTATTGTTCA GATGCCTCGAGGTGTCTAGTGTGCCACTGTTGCTATCAATAATAGCCAAAATGCCGGTATTTAGCCTGTCGTATACTTGCTACA TTTCAACCCTCC
<i>ura4</i> - HR template	TTGGAAGACATTTTCCAGCCAAAAGCAAGAGACCACGTCCCAAAGGTAACCACTTCTTTGAGGCCTTGATAATACCCTCGCCC TACACTGTATGGCAATTTGTGATATGAGCCCAAGACTAAATTTGTACACACCAGATGCATATTGTAGCTTGACGGTATTTCCAAT GTCTGCGAAT
<i>meu27</i> - HR template	GCCAAAATCAATAGAGAACAATTATACTTTAAAAAATAAAGGAAGGCTTCTTAAGTCAACAGGAAAATAAGTATTCAAATC AAAATCCTTCAAAGGCTAATAACCTTTTCGACAAGCTCGGCGTAAGCAAGCCAATAACATTCATAGCTTGATACTGCAATGGGC GGCACCTC
<i>clr5</i> - HR template	CTTATTTGCAGCAGCCTTTCCAAATACCCTCTCAACGTTTCTCTCGACAGCAACAATCTCATCCATCCCTGCTGCTCAACATGCA GTTAACGGTTAGCCACAAGCTTTGTATCCTTTCATCTACCAATCTAGAAATGTCCCAATGGGCTCCACCATGTTTGCTTCTTCAA CCAATCTG
<i>cup1:4xtetO</i> - HR template	TTGAATTAATTCATAGAGTATGATAAAAATTGATAGTAAATTCATTGGTATACTAAAGTGATGTAGAAAATTAAGAAATCACATAGAC TACTTGAGTTACGATGATTTATTAGCATGCAcaaggcctactagtcgatgcatgtagatcctctatcactgataggagatcctcctatcactgata gagaggatcctcctatcactgatagagaggatcctcctatcactgatagagaggatcctcctatcactgatagaggatcctcctatcactgatagg agatctcaacttggtgtaggtaaacgaaatccagTAAATATTATGAAAAAATAAATGATTCATAACAGCAGATGAAAATGATGA CGAATTAGGACTCTTCAAATAAATGAAGATTATACATTACAAA
<i>cup1</i> -GFP - HR template	ATGACGAATTAGGACTCTTCAAATAAATGAAGATTATACATTACAACTTTGGTCTGACTTTTTAAAGCACACGATTTGctatttga tagttcatccatgcatgtgtaatcccagcagctgttacaacctcaagaaggaccatgtggtctcttttcggtgggatctttcgaaggcagattgt gtggacaggtaatggtgtctggtgtaaaaggacagggccatcgcaattggagtattttgtgataatggtctgtagttgaacgcttcatcttcaatg tgtgtctaattttgaagttaacttggattcattctttgttctgctccatgataacattggtgagttatagttgattccaattgtgtccaag aatgtttccatcttcttaaaatcaataccttttaactcgtattcttaaacagggtatcaccttcaactgactcagcagctgtctgtagtctccg tcatctttgaaaaatagttcttctgtacataaccttggcctgcatgcaactcttgaagaagcatgccgttcatatgatctgggtatcttgaagaagc attgaacaccataagtgaaagtagtgacaaggttgccatggaacaggtagtttccagtagtgcaataaattgaaggtaagtttccgatgttgc atcacctcactcctcactgacagaaaatttggccataacatcacatcaattcaacaagaattgggacaactcagtgaaaagttcttctct ttactCCTTTTTTACTGACTTTTTTAAAGAACCTTTCCGACGTTTAGCCTGAGCTGAATGTCTGACAAAGAGTCCACGATACAA
<i>epe1Δ</i> - HR template	GTGAACTACTCAAGAATCATAAGCACGTGGGATAAATATCAATGGTAGCCGAAGGAATAAAAAGTGCCGAGGTACTTCTTA AAAGTCCCAAAAATTA
<i>3xFLAG-epe1</i> - HR template	GAATATCAATGTCTTGATTATAATGTCATCGTATTCAAGCCAGGAATCGCTGCCTCCTCCCTTGTCATCGTCATCCTGTAGTCG ATGTCATGATCTTATAATCACCGTCATGGTCTTTGTAGTCCATCTAAAAGTCCCAAAAATTAATGCTTACTAGCAAAAAGGTAA CTATAAA

use of G1-synchronized cell cultures for CRISPR/Cas9-mediated genome manipulation reduces the efficiency of targeted mutagenesis, with both the *SpEDIT* and pMZ379 systems, relative to asynchronous cultures (Figure 3). G1 synchronization therefore represents an unnecessary time-consuming step in the genome editing process.

*SpEDIT* can be used to introduce simultaneous mutations at two non-homologous genes at distinct locations in the *S. pombe* genome (Figure 5), and allows flexible engineering of seamless insertion, deletion and tagging events at *S. pombe*

loci in the absence of linked selectable markers and without observed off-target sequence changes (Figure 6). It is worth noting that many traditional *S. pombe* transformation protocols involve the use of carrier DNA. We advise against the use of carrier DNA as it has been shown to insert at many locations in resulting transformants, causing unplanned off-target mutations (Longmuir *et al.*, 2019).

Besides achieving high mutagenesis efficiency, the greatest advance of *SpEDIT* is a very simple cloning protocol allowing sgRNA target sequences to be inserted with minimal effort

into the Cas9-bearing pLSB plasmid through a one-step Golden Gate reaction. Candidate sgRNA-bearing clones are easily visualized by loss of the GFP placeholder, negating the need for repetitive screening of numerous *E. coli* colonies by laborious plasmid purification and inspection.

Recently it was reported that homology arms of as short as 25 bp flanking each side of a cleavage site can be used to successfully introduce point mutations and epitope tags at *S. pombe* loci (Hayashi & Tanaka, 2019). Further analyses will be required to determine whether HR templates with such short homology arms are as efficient as longer arms when combined with *SpEDIT*. In addition, the tDNA/HDV ribozyme sgRNA expression cassette that was originally developed for *S. cerevisiae* has been used to express up to three tandem HDV-sgRNAs from a single tDNA RNAPIII promoter with 80% mutagenesis efficiency (Ryan *et al.*, 2014). This suggests that a similar approach could be used with *SpEDIT* to simultaneously express multiple different sgRNAs that target a single locus or many distinct loci.

In summary, the combination of the CRISPR4P algorithm (Rodríguez-López *et al.*, 2016), that conveniently aids the identification of suitable sgRNAs across the *S. pombe* genome, with *SpEDIT*, which provides a straightforward and user-friendly experimental method, markedly enhances the capabilities of CRISPR/Cas9-mediated genome editing in *S. pombe*. We anticipate *SpEDIT* will permit the broad application of genome editing procedures to fission yeast in order to explore diverse biological questions in this model fungal system.

## Methods

### pLSB construction

For pLSB-NAT construction, the Cas9 gene and the strong *adh1* promoter present in pMZ379 (plasmid generated by Mikel Zarategui and provided by Jürg Bähler (Rodríguez-López *et al.*, 2016)), were replaced by a Cas9 gene codon-optimised for *S. pombe* (custom synthesised, Gen9) and the medium strength *adh15* promoter (from pRAD15, gift from Yoshi Watanabe), respectively, via Gibson Assembly (New England Biolabs, Cat# E2611). Next, the *rrk1/HHR* sgRNA cassette present in pMZ379 was replaced by the tDNA/HDV sgRNA cassette (custom synthesised, Gen9) via Gibson Assembly (New England Biolabs, Cat# E2611). *BsaI* sites flanking the GFP placeholder in the tDNA/HDV sgRNA cassette were then introduced using Q5 Site-Directed Mutagenesis Kit (New England Biolabs, Cat# E0554).

To construct pLSB versions with *kanMX6* (pLSB-Kan, G418 resistance) or *hphMX6* (pLSB-Hyg, hygromycin resistance) selectable markers, the *natMX6* gene from pLSB-NAT was replaced by the *kanMX6* or *hphMX6* genes from *pFA6a-kanMX6* (Bähler *et al.*, 1998) or *pFA6a-hphMX6* (Hentges *et al.*, 2005) plasmids, respectively, by Gibson Assembly (New England Biolabs, Cat# E2611).

sgRNA and HR template sequences can be found in Table 1. All sgRNA sequences used were obtained using CRISPR4P

(Rodríguez-López *et al.*, 2016). Oligonucleotide sequences are listed in Table 2.

### Yeast strains and manipulations

Standard methods were used for fission yeast growth, genetics and manipulation (Moreno *et al.*, 1991). *S. pombe* strains generated in this study are described in Table 3. 972 *h* wild-type cells were used for all experiments.

Competent cryopreserved G1-synchronized *S. pombe* cells were prepared as described in Rodríguez-López *et al.* (2016). Wild-type cells were grown to a concentration of  $1 \times 10^7$  cells per mL in EMM media and harvested at  $3500 \times g$  for 2 min. Cells were then resuspended in EMM-N and incubated for 2 hrs at 25°C until cells were of a small round morphology. Following three washes with ice-cold H<sub>2</sub>O, cells were resuspended in 2 mL of ice-cold 30% glycerol, 0.1 M lithium acetate (pH 4.9) and 50 µL aliquots were made and stored at -80°C until further usage.

Competent cryopreserved G1-synchronized *S. pombe* cells were transformed using the lithium acetate/PEG method (Sabatino & Forsburg, 2010), as described in Rodríguez-López *et al.*, 2016. Aliquots of cryopreserved, G1-synchronised cells were thawed at 40°C for 2 min. 200 ng of empty or sgRNA-containing pLSB or pMZ379 plasmid DNA, 250–1000 ng of HR template DNA (when applicable) and 145 µL of 50% PEG 4000 were added to the cells and mixed thoroughly. Note that herring sperm DNA was omitted due to concerns regarding the erroneous integration of these fragments at the targeted loci as described in Longmuir *et al.* (2019). Cells were then resuspended in 1 mL of EMM-N and incubated for 16 hrs at room temperature. Following incubation, cells were resuspended in 500 µL H<sub>2</sub>O and plated onto YES plus cloNAT media. Plates were incubated at 32°C for 3–5 days.

Asynchronous cultures of *S. pombe* cells were transformed by electroporation. 50 mL cultures were grown to log phase ( $5 \times 10^6$  to  $1 \times 10^7$  cells per mL) in YES media and harvested at  $3500 \times g$  for 2 min. Cells were resuspended in 5 mL of pre-transformation buffer (25 mM DTT, 0.6 M sorbitol, 20 mM HEPES, pH 7.6) and incubated at 32°C for 10 min. Cells were then washed three times in 10 mL of 1.2 M ice-cold sorbitol and resuspended in 500 µL of 1.2 M ice-cold sorbitol. 200 µL cells were added to 200 ng of empty or sgRNA-loaded pLSB or pMZ379 plasmid DNA and 250–1000 ng of HR template DNA (when applicable) in an ice-cold electroporation cuvette. Cells were pulsed using a Gene Pulser II electroporation system (Bio-Rad) with *S. pombe* settings: 2.25 kV, 200 Ω and 25 µF. Immediately following pulse, cells were rapidly mixed with 500 µL of 1.2 M ice-cold sorbitol. Cells were grown overnight in 10 mL of non-selective YES medium before plating on selection (YES plus cloNAT, YES plus G418 or YES plus hygromycin depending on pLSB version used). Plates were incubated at 32°C for 3–5 days. cloNAT, nourseothricin.

To assess colony area of pLSB- or pMZ379-harboring cloNAT-resistant colonies, plates were scanned after four days

**Table 2. Oligonucleotides used in this study.**

Name	Sequence
Making <i>ade6</i> – sgRNA - F	CtagaGGTCTCgGACTTTGATAGCAACAGTGGCGACGTTTcGAGACCttCC
Making <i>ade6</i> – sgRNA - R	GGaagGGTCTCgAAACGTCGCCACTGTTGCTATCAAAGTcGAGACCtctaG
Making <i>ura4</i> – sgRNA - F	CtagaGGTCTCgGACTCCTGTATAATACCCTCGCCGTTTcGAGACCttCC
Making <i>ura4</i> – sgRNA - R	GGaagGGTCTCgAAACGCGAGGGTATTATAACAAGGATCcGAGACCtctaG
Making <i>meu27</i> - sgRNA - F	CtagaGGTCTCgGACTTATTAGCCTTTGAAGGATTTGTTcGAGACCttCC
Making <i>meu27</i> - sgRNA - R	GGaagGGTCTCgAAACAATCCTTCAAAGGCTAATAAGTcGAGACCtctaG
Making <i>clr5</i> – sgRNA - F	CtagaGGTCTCgGACTAGCTTGTGGCTGACCGTTAAGTTTcGAGACCttCC
Making <i>clr5</i> – sgRNA - R	GGaagGGTCTCgAAACTAACGGTCAGCCACAAGCTAGTcGAGACCtctaG
Making <i>cup1:4xtetO</i> – sgRNA - F	CtagaGGTCTCgGACTATTTCTTTGCTTTACGGTCGTTTcGAGACCttCC
Making <i>cup1:4xtetO</i> – sgRNA - R	GGaagGGTCTCgAAACGACCGTAAAGCAAAGAAATAGTcGAGACCtctaG
Making cup1-GFP – sgRNA - F	CTAGAGGTCTCGGACTGCTCAGGCTAAACGTCGGAAGTTTcGAGACCCTTCC
Making cup1-GFP – sgRNA - R	GGAAGGGTCTCGAAACTTCCGACGTTTAGCCTGAGCAGTCCGAGACCTCTAG
Making <i>epe1</i> – sgRNA - F	CtagaGGTCTCgGACTGGACTTTTAAGATGGATTCCGTTTcGAGACCttCC
Making <i>epe1</i> – sgRNA - R	GGaagGGTCTCgAAACGGAATCCATCTTAAAAGTCCAGTcGAGACCtctaG
Making <i>ade6</i> - HR template - F	GCAATGACACCTCTTCCAGTAATCGGCG TTCCTGTAAAAGGAAGCACTCTTGACGG AGTTGACTCTCTTTA GTCTATTGTTGAGA TGCCTCGAGGTGTCT
Making <i>ade6</i> - HR template - R	GGAGGGTTGAAATGTAGCAAGTATACGA CAGGCTAAAATACCGGCATTTTGGCTATT TATTGATAGCAACA GTGGCGACCTAGACA CCTCGAGGCATCTGA
Making <i>ura4</i> - HR template - F	TTGGAAGACATTTCCAGCCAAAAGCAAGA GACCACGTCCCAAAGGTAACCAACTTC TTTGAGGCCTTGAT AATACCCTCGCCCT AACTGTATGGCAAT
Making <i>ura4</i> - HR template - R	ATTTCGACGACATTGGAATACCGTCAAG CTACAATATGCATCTGGTGTGTACAAAAT TTAGTCTTGGGCTCA TATCACAAATTGCC ATACAGTGTAGGGC
Making <i>meu27</i> - HR template - F	GCCAAAATCAATAGAGAACAATTATACTTTAAAAAAAAAAAAATGAAGAAGGCTTCTTAAGTCAACAGGAAAAT AAGTATTCAAATCAAATCCTTCAAAG
Making <i>meu27</i> - HR template - R	GAGGTGCCGCCAATTGCAGTATACAAGCTATGAATGTATTGGCTTGCTTACGCCGAGCTTGTGCAAAAAGG TTATTAGCCTTTGAAGGATTTTGATTTG
Making <i>clr5</i> - HR template - F	CTTATTGTCAGCAGCCTTTCCAAATACCCTCTCAACGTTTCTCTCGACGCAACAATCTCATCCATTCCCTGCT GCTCAACATGCAGTTAACGGTTAGCC
Making <i>clr5</i> - HR template - R	CAGATTGGTTTGAAGAAGCAAACATGGTGGAGCCATTGGGACATTTCTAGATTGGTAGATGAAAGGATAC AAAGCTTGTGGCTAACCGTTAACTGCATG
Making <i>cup1:4xtetO</i> - HR template - 1 - F	TTGAATTAATTCATAGAGTATGATAAAAATTGATAGTAAATTCATTGG
Making <i>cup1:4xtetO</i> - HR template - 1 - R	cactagtaggacctgATGCATGCTAATAAATCATCGTAACTCAAGTAG
Making <i>cup1:4xtetO</i> - HR template - 2 - F	TTTATTAGCATGCATcaaggcctactagtgcatgca
Making <i>cup1:4xtetO</i> - HR template - 2 - R	TTTTTTTTTTCATAAATATTTActggatttcgttacctcaccacc
Making <i>cup1:4xtetO</i> - HR template - 3 - F	tggtgaggtaaacgaaatccagTAAATATTATGAAAAAAAAATAAATGATTCATAACAAGCAGATGAAAA
Making <i>cup1:4xtetO</i> - HR template - 3 - R	TTTGTAAATGATAATCTTCATTTATTTTGAAGAGTCCTAATTCGT

Name	Sequence
Making cup1-GFP - HR template - F	ATGACGAATTAGGACTCTTCAAATAAATGAAGATTATACATTACAACTTTGGTCTGACTTTTTAAAGCACAC GATTTGCTATTGTATAGTTCATCCA
Making cup1-GFP - HR template - R	TTGTATCGTGGGACTCTTTGTCAGACATTCAAGCTCAGGCTAAACGTCGGAAAAGTTCTTAAAAAGTCAGTCA AAAAAAGGAGTAAAGGAGAAGAAGTCTTT
Making <i>epe1Δ</i> - HR template - F	GTGAACTACTCAAGAATCATAAGCACGTGGGGATAAATATTCAATGGTAGCCGAAGGAAATAAAAAGTGCCG AGGTACTTCTTAAAAGTCCCAAAATTA
Making <i>epe1Δ</i> - HR template - R	CCATAGAATCTCTTAGTTTGCATCGCAATTTTATAGTTACCTTTTGTAGTAGCAATTAATTTTTGGGACTT TTAAGAAGTACCTCGGCACTTTT
Making 3xFLAG- <i>epe1</i> - HR template - F	TTTATAGTTACCTTTTGTAGTAGCAATTAATTTTTGGGACTTTTAAAGTGGACTACAAGACCATGACGGT GATTATAAAGATCATGACATCGACTA
Making 3xFLAG- <i>epe1</i> - HR template - R	GAATATCAATGTCTTGATTATAATGTCATCGTATTCAAGCCAGGAATCGCTGCCTCCTCCCTTGTGCATCGTCAT CCTTGTAGTCGATGTCATGATCTTT
Checking mutations <i>ade6</i> - F	TTGTTTCAGCTCACCGACA
Checking mutations <i>ade6</i> - R	AAAGCAAGCAAATCATTTAACAGT
Checking mutations <i>ura4</i> - F	GCTCCATAGACTCCACGACC
Checking mutations <i>ura4</i> - R	TTGTCAGTCGCGGTGATTT
Checking mutations <i>meu27</i> - F	AAATTTGCGCTCCTCTCTGC
Checking mutations <i>meu27</i> - R	GTTTGGTATTTACGAGCTGCCA
Checking mutations <i>clr5</i> - F	CACACAATGCGCACTCTTCT
Checking mutations <i>clr5</i> - R	ACAGCAGTTGGTCCGTTAGA
Checking <i>cup1:4xtetO</i> - F (A1)	GGTTAGGCAGAAGACTTGAGCA
Checking <i>cup1:4xtetO</i> - R (A2)	ATCATCACTTGCACTCACTTCTCT
Checking cup1-GFP - F	GGCGAAGCTTTTAAGTCTGAAGG
Checking cup1-GFP - R	GCTGTCCCACTTTACCACA
Checking <i>epe1Δ</i> - F (C1)	CAAATCTAACGAGTTTGCCTGC
Checking <i>epe1Δ</i> - R (C3)	GCAAACAACGAGTCAAAGTGGA
Checking <i>epe1 cds</i> - F (C2)	GGGCGAGCGACAATCATAA
Checking 3xFLAG- <i>epe1</i> - F	AGTGAGGCTGTGCAAAGGAA
Checking 3xFLAG- <i>epe1</i> - R	TCTAACGAGTTTGCCTGCTT
M13F	GTAAAACGACGGCCAGT

**Table 3.** *Schizosaccharomyces pombe* strains used in this study.

Strain number	Name	Description
143	wt	<i>h</i> - ED972 wild-type
B4752	Clr5-Q264STOP Meu27-S100Y	<i>h</i> - <i>clr5</i> -Q264STOP <i>meu27</i> -S100Y
B3808	<i>cup1:4xtetO</i>	<i>h</i> - <i>4xtetO</i> 3' of <i>cup1</i> <i>leu1</i> -32 ( <i>cup1</i> =SPBC17G9.13c)
B4567	Cup1-GFP	<i>h</i> - <i>cup1</i> -GFP ( <i>cup1</i> =SPBC17G9.13c)
B4621	<i>epe1Δ</i>	<i>h</i> - <i>epe1Δ</i>
B4958	3xFLAG-Epe1	<i>h</i> - 3xFLAG- <i>epe1</i>

of incubation. Images were then analysed using ImageJ (v1.51) (analyse particles) with default settings.

### Assessing mutations at the *ade6* and *ura4* loci

Colonies harbouring mutations at the target genes *ade6*<sup>+</sup> or *ura4*<sup>+</sup> were identified through a replica-plating assay. cloNAT-resistant colonies were individually picked from YES plus cloNAT plates, re-streaked onto YES plates without selection and incubated at 32°C for two days. Isolates were then replica-plated onto the following plates: YES, YES 1/10 adenine (to examine *ade6*<sup>+</sup> mutations), PMG minus uracil and PMG plus 5-fluoroorotic acid (to examine *ura4*<sup>+</sup> mutations). Plates were incubated at 32°C for 2–4 days and then visually examined.

### Colony PCR and Sanger sequencing

A small amount of fission yeast cells (~1 × 10<sup>4</sup>) from individual single colonies was incubated in 10 µL of SPZ buffer (1.2 M sorbitol, 100 mM sodium phosphate, 2.5 mg/mL Zymolyase 100T (AMS Biotechnology)) at 37°C for approximately 1 hr. 40 µL H<sub>2</sub>O was added to the cells and 5 µL of the extract was used as a PCR template. PCRs were performed using 0.5U *Taq* Polymerase (Roche, Cat# 11147633103), 1 µM oligonucleotides, and the following conditions on a standard thermocycler: 94°C for 4 min; 29 cycles of 94°C for 30 sec, 55°C for 30 sec and 72°C for 1 min; and a final step of 72°C for 5 min. PCR products were analysed on a 1% agarose gel, purified using Monarch PCR Cleanup Kit (New England Biolabs, Cat# T1030) and sequenced using BigDye Terminator Cycle sequencing kit (Thermo Scientific, Cat# 4337458).

### Protein extraction and western analysis

Protein samples were prepared as previously described (Torres-Garcia *et al.*, 2020). Western blotting detection was performed using mouse monoclonal anti-FLAG-HRP (Sigma, Cat# A8591, RRID:AB\_439702), rabbit polyclonal anti-GFP (Invitrogen, Cat# A11122, RRID:AB\_2307355) and goat polyclonal anti-rabbit-HRP (Sigma, Cat# A6154, RRID:AB\_258284).

### *SpEDIT* protocol

A convenient protocol card of this procedure can be found by visiting [allshirelab.com/spedit](http://allshirelab.com/spedit) or by scanning the QR code in Figure 1.

### Before you begin

- Download required DNA sequences at [allshirelab.com/spedit](http://allshirelab.com/spedit), on Zenodo (Torres-Garcia, 2020) or by scanning the QR code in Figure 1

### Required reagents

- pLSB vector (75 ng/µL) – Available on request
- NEB Golden Gate Assembly Kit (*Bsa*I-HF v2) – NEB #E1601S
- sgRNA fragment for Golden Gate assembly (1 ng/µL) – See below for design and preparation

- HR template (250-1000 ng) – See below for design and preparation

### sgRNA design

- Find a suitable sgRNA targeting the gene of interest using CRISPR4P (Rodríguez-López *et al.*, 2016)
- Copy the 20 bp sgRNA sequence in place of 'your 20 bp targeting RNA' in 'GG\_sgRNA\_template.dna' file
- Order 52-nt forward and reverse sgRNA oligonucleotides as indicated in the 'GG\_sgRNA\_template.dna' file

### sgRNA fragment preparation

- Anneal sgRNA oligonucleotides
  - Mix 5 µL of 100 µM forward and reverse sgRNA oligonucleotides
  - Heat to 95°C for 3 min and cool down to room temperature slowly (e.g. -1°C/30 sec)
  - Add 1 µL of annealed mix to 1.5 mL of H<sub>2</sub>O. This dilution corresponds to approximately 1 ng/µL annealed sgRNA fragment.

### Golden Gate reaction

- Mix the following components in a PCR tube:
  - pLSB plasmid (75 ng/µL) – 0.5 µL
  - Annealed sgRNA fragment (1 ng/µL) – 0.5 µL
  - T4 DNA Ligase Buffer (10x) – 1 µL
  - NEB Golden Gate Assembly Mix (*Bsa*I-HF v2) – 0.5 µL
  - H<sub>2</sub>O – 7.5 µL
- Incubate at 37°C for 1 hr
- Incubate at 60°C for 5 min
- Transform into *Escherichia coli* by heat shock:
  - 1 µL of Golden Gate reaction to 25 µL of *DH5-alpha* or *10-Beta E. coli* cells
  - Place the mixture on ice for 30 min
  - Heat shock at exactly 42°C for exactly 30 sec
  - Place on ice for 5 min
  - Add 475 µL SOC media and recover cells at 37°C for 1 hr
  - Plate 200 µL / 100 µL / 50 µL / rest on LB plus ampicillin
- Select four *E. coli* colonies and set up liquid cultures in LB plus ampicillin
- Isolate plasmid (miniprep)
  - IMPORTANT: do not miniprep culture if green – these are GFP-containing clones where the Golden Gate reaction did not occur
  - One miniprep (approximately 200 ng/µL) should be sufficient for many *S. pombe* transformations (200 ng/transformation)



### Plasmid check

- Digest plasmid using *NcoI*
  - This digest allows sgRNA-containing plasmids to be distinguished from those containing GFP
- Sequence sgRNA-containing plasmids using M13F oligonucleotide (see [Table 2](#)) to confirm sgRNA insertion

### HR template design and preparation

- The HR template should contain:
  - Your desired mutation: point mutation, insertion, deletion or tag
  - At least 80 bp homology on each side relative to the cleavage site (3 bp upstream of PAM sequence (NGG))
  - A mutation that disrupts the PAM sequence to avoid repeated DSBs
    - If the total size of the HR template is equal or smaller than 180 bp, we recommend generating HR templates by PCR using oligonucleotides with overlapping at their 3' end as described in [Rodríguez-López et al., 2016](#)
    - If the total size of the HR template is larger than 180 bp, we recommend using a fusion PCR construct containing homology arms to the target site (see HR template for *cup1:4xtetO* in [Table 1](#))

### *S. pombe* transformation

- Transform *S. pombe* cells using your preferred method with sgRNA-loaded pLSB plasmid (200 ng) and HR template (500-1000 ng)
- Grow non-selectively o/n on YES plates or liquid
- Plate on YES plus cloNAT (or YES plus G418 or YES plus hygromycin depending on pLSB version used)
- Re-streak transformant colonies to non-selective media to allow loss of plasmid
- Amplify region of interest by colony PCR and sequence amplicon to confirm mutation

### Data availability

#### Underlying data

Whole-genome sequencing data for relevant strains are available on GEO, Accession number GSE138436: <https://identifiers.org/geo:GSE138436> (Torres-Garcia et al., 2020).

Zenodo: *SpEDIT*: A fast and efficient CRISPR/Cas9 method for fission yeast.

<https://doi.org/10.5281/zenodo.4247568> (Torres-Garcia, 2020)

This project contains the following underlying data:

- Fig\_3C.csv (Raw mutagenesis efficiency data underlying Figure 3C)
- Fig\_3D.csv (Raw mutagenesis efficiency data underlying Figure 3D)
- Fig\_4A.csv (Raw colony area measurements underlying Figure 4A)
- Fig\_4B.csv (Raw colony area measurements underlying Figure 4B)
- F6\_uncropped.pdf (Original, uncropped PCR gel and western blot images from Figure 6)

#### Extended data

Zenodo: *SpEDIT*: A fast and efficient CRISPR/Cas9 method for fission yeast.

<https://doi.org/10.5281/zenodo.4247568> (Torres-Garcia, 2020)

This project contains the following extended data:

- GG\_sgRNA\_template.dna (sgRNA sequence)
- pLSB\_Allshire.dna (pLSB plasmid sequence)

Data are available under the terms of the [Creative Commons Zero "No rights reserved" data waiver](#) (CC0 1.0 Public domain dedication).

### Acknowledgements

We thank Gabor Varga for technical assistance. We thank members of the Allshire lab for valuable discussions.

## References

- Audergon PNCB, Catania S, Kagansky A, et al.: **Epigenetics. Restricted epigenetic inheritance of H3K9 methylation.** *Science*. 2015; **348**(6230): 132–135.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Bähler J, Wu JQ, Longtine MS, et al.: **Heterologous modules for efficient and versatile PCR-based gene targeting in *Schizosaccharomyces pombe*.** *Yeast*. 1998; **14**(10): 943–951.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- Ciccaglione KM: **Adaptation of CRISPR/Cas9 to improve the experimental utility of the model system *Schizosaccharomyces pombe*.** Master's thesis

- Rutgers University. 2015.  
[Publisher Full Text](#)
- Cong L, Ran FA, Cox D, et al.: **Multiplex genome engineering using CRISPR/Cas systems.** *Science*. 2013; **339**(6121): 819–823.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Fantes PA, Hoffman CS: **A Brief History of *Schizosaccharomyces pombe* Research: A Perspective Over the Past 70 Years.** *Genetics*. 2016; **203**(2): 621–629.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Fernandez R, Berro J: **Use of a fluoride channel as a new selection marker**

- for fission yeast plasmids and application to fast genome editing with CRISPR/Cas9. *Yeast*. 2016; **33**(10): 549–557.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Hayashi A, Tanaka K: **Short-Homology-Mediated CRISPR/Cas9-Based Method for Genome Editing in Fission Yeast**. *G3 (Bethesda)*. 2019; **9**(4): 1153–1163.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Hentges P, Van Driessche B, Tafforeau L, et al.: **Three novel antibiotic marker cassettes for gene disruption and marker switching in *Schizosaccharomyces pombe***. *Yeast*. 2005; **22**(13): 1013–1019.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- Hottinger-Werlen A, Schaack J, Lapointe J, et al.: **Dimeric tRNA gene arrangement in *Schizosaccharomyces pombe* allows increased expression of the downstream gene**. *Nucleic Acids Res*. 1985; **13**(24): 8739–8747.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Hsu PD, Lander ES, Zhang F: **Development and applications of CRISPR-Cas9 for genome engineering**. *Cell*. 2014; **157**(6): 1262–1278.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Jacobs JZ, Ciccaglione KM, Tournier V, et al.: **Implementation of the CRISPR-Cas9 system in fission yeast**. *Nat Commun*. 2014; **5**: 5344.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Jinek M, Chylinski K, Fonfara I, et al.: **A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity**. *Science*. 2012; **337**(6096): 816–821.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Lock A, Rutherford K, Harris MA, et al.: **PomBase 2018: user-driven reimplementation of the fission yeast database provides rapid and intuitive access to diverse, interconnected information**. *Nucleic Acids Res*. 2019; **47**(D1): D821–D827.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Longmuir S, Akhtar N, MacNeill SA: **Unexpected insertion of carrier DNA sequences into the fission yeast genome during CRISPR-Cas9 mediated gene deletion**. *BMC Res Notes*. 2019; **12**(1): 191.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Mata J, Lyne, R, Burns G, et al.: **The transcriptional program of meiosis and sporulation in fission yeast**. *Nat Genet*. 2002; **32**(1): 143–147.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- Moreno S, Klar A, Nurse P, et al.: **Molecular genetic analysis of fission yeast *Schizosaccharomyces pombe***. *Methods Enzymol*. 1991; **194**: 795–823.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- Orthwein A, Noordermeer SM, Wilson MD, et al.: **A mechanism for the suppression of homologous recombination in G1 cells**. *Nature*. 2015; **528**(7582): 422–426.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Ragunathan K, Jih G, Moazed D, et al.: **Epigenetics. Epigenetic inheritance uncoupled from sequence-specific recruitment**. *Science*. 2015; **348**(6230): 1258699.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Rodríguez-López M, Cotobal C, Fernández-Sánchez O, et al.: **A CRISPR/Cas9-based method and primer design tool for seamless genome editing in fission yeast [version 3; peer review: 2 approved]**. *Wellcome Open Res*. 2016; **1**: 19.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Ryan OW, Skerker JM, Maurer MJ, et al.: **Selection of chromosomal DNA libraries using a multiplex CRISPR system**. *eLife*. 2014; **3**: e03703.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Sabatinos SA, Forsburg SL: **Molecular genetics of *Schizosaccharomyces pombe***. *Methods Enzymol*. 2010; **470**: 759–795.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- Sorida M, Hirauchi T, Ishizaki H, et al.: **Regulation of ectopic heterochromatin-mediated epigenetic diversification by the JmjC family protein Epe1**. *PLoS Genet*. 2019; **15**(6): e1008129.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Torres-García S, Yaseen I, Shukla M, et al.: **Epigenetic gene silencing by heterochromatin primes fungal resistance**. *Nature*. 2020; **585**(7825): 453–458.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- Torres-García S: **SpEDIT: A fast and efficient CRISPR/Cas9 method for fission yeast [Data set]**. *Zenodo*. 2020.  
<http://www.doi.org/10.5281/zenodo.4247568>
- Trickey M, Grimaldi M, Yamano H, et al.: **The anaphase-promoting complex/cyclosome controls repair and recombination by ubiquitylating Rhp54 in fission yeast**. *Mol Cell Biol*. 2008; **28**(12): 3905–3916.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Wang J, Reddy BD, Jia S, et al.: **Rapid epigenetic adaptation to uncontrolled heterochromatin spreading**. *eLife*. 2015; **4**: e06179.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Yamagishi Y, Sakuno T, Shimura M, et al.: **Heterochromatin links to centromeric protection by recruiting shugoshin**. *Nature*. 2008; **455**(7210): 251–255.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- Zhang XR, He JB, Wang YZ, et al.: **A Cloning-Free Method for CRISPR/Cas9-Mediated Genome Editing in Fission Yeast**. *G3 (Bethesda)*. 2018; **8**(6): 2067–2077.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Zhao Y, Boeke JD: **Construction of Designer Selectable Marker Deletions with a CRISPR-Cas9 Toolbox in *Schizosaccharomyces pombe* and New Design of Common Entry Vectors**. *G3 (Bethesda)*. 2018; **8**(3): 789–796.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Zofall M, Yamanaka S, Reyes-Turcu FE, et al.: **RNA elimination machinery targeting meiotic mRNAs promotes facultative heterochromatin formation**. *Science*. 2012; **335**(6064): 96–100.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

# Open Peer Review

Current Peer Review Status:   

---

## Version 1

Reviewer Report 15 January 2021

<https://doi.org/10.21956/wellcomeopenres.18048.r41572>

© 2021 Braun S et al. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



**Sigurd Braun** 

Ludwig Maximilians University of Munich, Martinsried, Germany

**Thomas van Emden** 

Ludwig Maximilians University of Munich, Martinsried, Germany

Torres-Garcia and colleagues report an improved method for scarless genome editing in *S. pombe* by CRISPR/Cas9. This method coined *SpEDIT* overcomes limitations of previous CRISPR protocols (e.g., Jacobs *et al.*, 2014; Rodriguez-Lopez *et al.*, 2016)<sup>1,2</sup> that are plagued by tedious cloning procedures to integrate sgRNAs into suitable expression vectors and the toxicity of overexpressed Cas9 endonuclease.

For their new expression system, the authors replaced the Cas9 gene with an *S. pombe* codon-optimized Cas9 gene expressed from the medium-strength *adh15* promoter, a derivative of the strong *adh1* promoter (Yamagishi *et al.* 2008)<sup>3</sup>. For the expression of the sgRNA, they adopted an expression system successfully used in *S. cerevisiae* (Ryan *et al.* 2014)<sup>4</sup>, consisting of an RNA polymerase III-driven tRNA gene/hepatitis delta virus ribozyme (HDV) sequence that creates a defined 5' transcript and improves sgRNA stability and genome editing. The tDNA/HDV cassette further allowed insertion of two *BsaI* restriction sites for one-step cloning of the sgRNA by the Golden Gate cloning system. In addition, they inserted a GFP sequence as a placeholder within the *BsaI* sites for visual inspection of positive *E. coli* clones. Together, this modular design significantly improved the cloning procedure compared to previous methods that are hampered by the use of an inconvenient restriction enzyme (*CspCI*) or tedious PCR-based cloning methods. Moreover, by offering multiple expression vectors with different selection markers (*natMX6*, *kanMX*, or *hphMX*), *SpEDIT* allows versatile use in different strain backgrounds.

The authors demonstrate that *SpEDIT* works 100% efficiently when introducing single-point mutations into the *ura4+* and *ade6+* gene nearby PAM sites. They further showed that using G1-synchronized cells for transformation is not necessary to achieve high efficiency, as was previously reported (Rodriguez-Lopez *et al.*, 2016)<sup>2</sup>. Moreover, they demonstrated that *SpEDIT* can also be applied for other gene-editing steps, like gene deletions, insertions, or truncations, as well as the simultaneous editing of two unrelated genetic loci using expression plasmids with different

selection markers. However, the efficiency of these more challenging genetic alteration was significantly lower (about 10-20%) compared to introducing single point mutations.

### Conclusion:

The CRISPR/Cas9 system presented here overcomes previous technical hurdles and significantly improves the usability of Cas9 based genome editing in *S. pombe*. The manuscript is well written, and the protocol is easy to follow. The authors have shared their system with my lab, and we have successfully used it to introduce mutations into several genes, confirming the efficiency of this system. Though, we did notice that editing at some loci is more challenging. Previous studies (e.g., Rodriguez-Lopez *et al.*, 2016)<sup>2</sup> have analyzed a larger number of genomic targets and compared different sgRNAs to assess the efficiency of the editing method. Thus, the reported high efficiency for *ade6+* and *ura4+* may not always be achieved for other genomic targets. Furthermore, while several parameters have been changed compared to existing methods, it is sometimes unclear how these changes (e.g., codon-optimization, reduced expression) have improved efficiency (see comments below). Maybe, the authors could provide more information in a revised version, which may clarify some of the points mentioned below.

### Comments and questions:

- For comparing SpEDIT with a previous method reported by the Bähler Lab (Rodriguez-Lopez *et al.*, 2016)<sup>2</sup>, the authors assessed mutagenesis efficiency and correct editing in Figure 3C, D. When using matching sgRNAs and HR templates, both methods seem to work equally efficiently for asynchronous cells. In contrast, differences were found for mismatching or no templates, as demonstrated by plotting mutant phenotypes as percentage relative to the total number tested. However, we wonder whether plotting the actual number of clones with mutant phenotypes would be more informative than plotting percentage. While percentage includes information on false positives, which is in principle meaningful, this analysis may be skewed when analyzing different total numbers of samples, especially for low numbers. For instance, for analyzing *ade6* mutations, both pLSB with pMZ379 resulted in similar numbers of clones with mutant phenotypes when using the correct HR template (150 vs. 150), non-correct HR template (12 vs. 26), or no HR template (0 vs. 1). However, by plotting percentages (i.e., number of clones with mutant phenotypes relative to total) the difference between both plasmids seems much larger (e.g., 0% vs. 100% for no template). This may reflect noise due to low sample numbers, but this does not immediately become clear when looking at the graphs. The same applies to the tables shown in Figure 3E. Also, providing here exact numbers (e.g., 5/5 or 4/5) seems more accurate and informative (especially when only 1 or 2 clones have been tested).
- The authors emphasize that they codon-optimize the Cas9 sequence and that its reduced expression results in decreased toxicity; however, how does this contribute to improved editing or a more user-friendly procedure? While the pLSB plasmid decreased toxicity in asynchronous cells compared to pMZ379, this did not improve gene editing efficiency for inserting single point mutations in *ura4+* and *ade6+*. Did the authors also compare the two plasmids for editing other targets or introducing more rate-limiting changes (e.g., deletions or insertions)?
- What is the expression strength of *adh15* promoter? (for comparison: for the *adh1* gene, 400 RNA molecules/cell have been reported).

- How does using electroporation affects transformation efficiency compared to chemical transformation? Is there a difference in the number of colonies after transformation with pLSB vs. pMZ379? Along the same line, to what extent is the comparison of gene editing using asynchronous and G1 synchronized cells confounded by using different transformation methods?

### References

1. Jacobs JZ, Ciccaglione KM, Tournier V, Zaratiegui M: Implementation of the CRISPR-Cas9 system in fission yeast. *Nat Commun*. 2014; **5**: 5344 [PubMed Abstract](#) | [Publisher Full Text](#)
2. Rodríguez-López M, Cotobal C, Fernández-Sánchez O, Borbarán Bravo N, et al.: A CRISPR/Cas9-based method and primer design tool for seamless genome editing in fission yeast. *Wellcome Open Research*. 2016; **1**. [Publisher Full Text](#)
3. Yamagishi Y, Sakuno T, Shimura M, Watanabe Y: Heterochromatin links to centromeric protection by recruiting shugoshin. *Nature*. 2008; **455** (7210): 251-5 [PubMed Abstract](#) | [Publisher Full Text](#)
4. Ryan OW, Skerker JM, Maurer MJ, Li X, et al.: Selection of chromosomal DNA libraries using a multiplex CRISPR system. *Elife*. 2014; **3**. [PubMed Abstract](#) | [Publisher Full Text](#)

### Is the rationale for developing the new method (or application) clearly explained?

Yes

### Is the description of the method technically sound?

Yes

### Are sufficient details provided to allow replication of the method development and its use by others?

Yes

### If any results are presented, are all the source data underlying the results available to ensure full reproducibility?

Yes

### Are the conclusions about the method and its performance adequately supported by the findings presented in the article?

Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Fission yeast, genetics, molecular biology.

**We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.**

Reviewer Report 04 December 2020

<https://doi.org/10.21956/wellcomeopenres.18048.r41573>

© 2020 Martin S. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



**Sophie Martin** 

Universite de Lausanne, Lausanne, Switzerland

This manuscript by Torres-Garcia and colleagues presents an improved CRISPR/Cas9 method for genome engineering in the fission yeast *S. pombe*. The main improvements over previously described methods are reduced toxicity of the Cas9 plasmid and greater ease of cloning of the sgRNA. They show that the method is highly efficient for introduction of point mutations and can also be used to introduce point mutations in two loci simultaneously or to insert or delete longer sequences.

The manuscript is well presented and convincing. The authors have already distributed their reagents, and my lab has used them with success. I can thus confirm that the method is functional and easy to use. It is likely to become widely used in the community. My comments below are mainly asking for some clarification.

One question that is not addressed is why Cas9 is toxic. The readout is small colony size, but whether this is linked to Cas9 binding the genome and/or inducing cuts is not clear. The authors cite a master thesis, which reports that toxicity is not linked to Cas9 catalytic activity, which is interesting, but to my knowledge this has not been probed further. I would suggest spelling out that the reason for toxicity is unclear and incite researchers to use the method with care.

I was also puzzled by why the target site appears to be more efficiently mutated when cells are co-transformed with an irrelevant HR template than with no HR template (Figures 3C-D). Any thought about this?

What is the efficiency of sequence insertion/tagging/deletion? The text states that 8 clones needed to be analysed to find at least 1 positive one. This suggests lower success rate than for the point mutations. It would be informative to state the results fully and make this point clear.

#### **Regarding the methodology:**

- The authors used Golden Gate to clone the sgRNA sequence in pLSB, but in principle other cloning strategies (including standard T4-ligase-based strategies) are possible. This would be good to indicate.
- A similar point goes for the transformation strategy. The authors state in the text that they used electroporation, which is not the most widely used strategy in yeast labs. However, in the protocol, they state that any transformation strategy can be used. Does this matter?
- In Figure 2C, I would suggest modifying the scheme to better indicate the difference of colour of the colonies (rather than cultures). The scheme seems to indicate that all will be picked and grown, and that the green cultures will be discarded, but in reality, one only picks from the non-green ones.

#### **Regarding data accessibility:**

- The whole-genome sequencing, stated to have revealed no additional genetic change, is not very easy to find in the cited manuscript, or even the GEO accession number provided. I would suggest a direct reference to sequencing of the strain. For instance, I could identify that one was accession GSM4407513, but was not sure of the others.
- In the data source for Figures 4A-B, the name of the image file that was likely quantified is not particularly useful without the actual image.

Finally, I would encourage the authors to deposit the pLSB vector in repository centers such as the [Japanese National BioResource Project](#) or [Addgene](#).

**Is the rationale for developing the new method (or application) clearly explained?**

Yes

**Is the description of the method technically sound?**

Yes

**Are sufficient details provided to allow replication of the method development and its use by others?**

Yes

**If any results are presented, are all the source data underlying the results available to ensure full reproducibility?**

Yes

**Are the conclusions about the method and its performance adequately supported by the findings presented in the article?**

Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Fission yeast, genetics, cell biology

**I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.**

Reviewer Report 25 November 2020

<https://doi.org/10.21956/wellcomeopenres.18048.r41575>

© 2020 Carr A. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



**Antony Carr** 

Genome Damage and Stability Centre, University of Sussex, Brighton, Sussex, BN1 9RQ, UK

This paper describes a useful refinement of CRISPR/Cas9 editing in fission yeast. It will be beneficial to the fission yeast community. The refinements include reduced expression of Cas9 and a better way to clone the sgRNA sequence. A range of applications are tested and a clear protocol provided.

Minor points.

Some readers do not know what Golden Gate cloning entails. A brief summary and an additional panel, for example in Figure 2, would be very helpful for those people.

Abstract: "...driven by RNA polymerase III from a tRNA gene sequence." Feels clumsy.

Page 3 second para: "...where strand end resection..." delete strand, or specify more detail.

Page 4 second paragraph: "Insertion of sgRNA sequences targeting genomic regions of interest into the *rrk1* sgRNA expression cassette in current CRISPR/Cas9 systems for *S. pombe* relies on slow and arduous cloning procedures involving either traditional restriction digestion (Hayashi & Tanaka, 2019; Jacobs *et al.*, 2014) or PCR over a long template (Rodríguez-López *et al.*, 2016)." is a difficult sentence to read. It could be clarified and/or broken into several sentences.

Page 4 third para: "The tDNA<sup>Ser</sup> acts as a RNAPIII promoter and the self-cleaving ribozyme protects and defines the 5' end of the resulting sgRNA (Figure 2A and B)" I was expecting the figure to help explain how the ribozyme protects and defines the 5' end.

Page 5 first para: "...pink colonies develop on low (1/10) adenine-containing plates..." Please state here or in the methods what the concentration is.

**Is the rationale for developing the new method (or application) clearly explained?**

Yes

**Is the description of the method technically sound?**

Yes

**Are sufficient details provided to allow replication of the method development and its use by others?**

Yes

**If any results are presented, are all the source data underlying the results available to ensure full reproducibility?**

Yes

**Are the conclusions about the method and its performance adequately supported by the findings presented in the article?**

Yes

**Competing Interests:** No competing interests were disclosed.



**Reviewer Expertise:** Fission yeast molecular genetics.

**I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.**

---